By identifying genetic markers such as those in SLC6A3, DRD4, ADRA2A, COMT, DRD5, and SLC6A2 (Table 2), clinicians may be able to tailor ADHD treatment to individual patients, improving therapeutic outcomes and minimizing adverse effects. This evidence concerns the gene SLC6A3 and attention deficit-hyperactivity disorder.